PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the spotlight during a recent episode of The Bell2Bell podcast. During the podcast, PaxMedica chief medical officer David Hough and host Stuart Smith discuss key company achievements, including the company’s recent meeting with the U.S. Food and Drug Administration (“FDA”). Highlights mentioned during the podcast include the discussion with the FDA of data gathered from the company’s PAX-HAT 301 study and other comprehensive nonclinical programs. Hough explained that the study provided positive evidence regarding the company’s treatment for African Sleeping Sickness treatment; he also noted that the FDA acknowledged PaxMedica’s comprehensive nonclinical program, including safety pharmacology and toxicology studies. Hough discussed waivers granted for the studies, affirmed data relevance to the patient population and stated that the anticipated 2024 NDA submission underscores PaxMedica’s commitment to neglected tropical disease treatments. The Bell2Bell podcast is produced by IBN, a leading communications organization focused on linking public companies to the investment community.

To listen to the full podcast, visit https://ibn.fm/lA5ZR

To view the full press release, visit https://ibn.fm/tLmYE

About PaxMedica Inc.

PaxMedica is a forward-looking, clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and Human African Trypanosomiasis (“HAT”). The company’s portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. PaxMedica is dedicated to the continuous development and evaluation of its pioneering program, PAX-101, an intravenous suramin formulation that lies at the heart of the company’s efforts, particularly focused on innovative ASD and HAT treatment solutions. The company’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN